We also found that CCR6+ Tregs, but not their CCR6- counterpart, could dominantly enrich in tumor mass and potential inhibited the function of effector T cells in vivo (Xu et al., 2010; Xu et al., 2011). The gene discussed is CCR6; the disease is neoplasm.